The 53-page Annual Report for 2016 of the Home Office Animals in Science Regulation Unit (ASRU) was published on 12 March 2018. 1 It makes very interesting reading. In a Ministerial Foreword, Baroness Williams of Trafford, the Home Office Minister of State responsible for the administration of the Animals (Scientific Procedures) Act 1986 (ASPA), offers assurances of rigorous and robust regulation, and confirms that Replacement, Reduction and Refinement must remain at the heart of the UK regulatory system.
A Foreword by Will Young, Head of the ASRU, notes a move to an electronic licensing system, and the application of a framework to support establishments in the self-assessment of their practices, so that they can themselves identify their strengths and areas needing improvement. He says that the need for balance between the authorisation of legitimate activities and strong compliance (with the ASPA) is the main focus of the regulatory process. A few pages later, it is noted that the impact of a number of other regulatory systems must be taken into account, since "medicines cannot be brought to market without testing on animals; new chemicals need to be tested on animals to provide assurances on public safety; and a great deal of medical and biological research relies on animals". This leads to the question of whether the ASRU, with the support of its advisory body, the Animals in Science Committee (ASC), sees its role as maintaining the status quo, via its licensing and inspection systems, rather than actively seeking substantial changes in biomedical research and testing, in line with the Three Rs concept.
It has to be said that the progress on achieving reduction is not encouraging. The total number of procedures conducted in the UK fell steadily from 1987, when the ASPA first became effective, through the 1990s, reaching 2.73 million procedures in 1996. But the numbers then rose steadily from 2000, reaching 3.01 million in 2006, and continuing to rise to the 3.94 million procedures completed in 2016. 2 Meanwhile, a Comment by Edwina Bowles in the last issue of ATLA 3 pointed out that replace ment is a myth, since, for example, the EU legislation (with which the ASPA is compliant) is not being enforced when validated non-animal alternatives to animal procedures exist. In an Editorial in the same issue, 4 it was stated that laws are of no value if they are not actively and effectively enforced, and it was pointed out that the Home Office, the National Centre for the Three Rs (NC3Rs), and various governmental and industry associations, are ignoring strong evidence that the absence of toxicity in animal tests provides little or no evidential weight that adverse drug reactions will also be absent in humans. That is a very serious issue, since 95% of all new drugs have to be withdrawn after their acceptance and introduction for clinical use, because of lack of efficacy and/or adverse reactions in humans that had not been detected in preclinical testing, including tests on rodents, dogs and non-human primates. This matter is also taken up in a Comment in this issue of ATLA, 5 which concludes that one reason, among others, for the failure to insist on replacement in the EU, is "ineffective control by the animal experimentation regulators in individual Member States".
Given the oft-stated commitment to openness and transparency, surely the authors of these articles [3] [4] [5] are entitled to considered and informed responses to the points they have raised, not only from the ASRU, but also from the ASC and the NC3Rs.
As far as refinement is concerned, the self-reporting initiative is courageous and encouraging, as there is no reason to believe that scientific establishments in which animals are used do not, in general, have other than the highest standards of animal care and compliance with the ASPA. However, there are exceptions to this, as illustrated by 45 cases of non-compliance spelled out in the ASRU Report. 1 These failures were of three main types:
-procedures conducted without authority; -failure to provide food and water; and -the unauthorised re-use of animals.
In one case, a personal licence holder used a nonhuman primate under general anaesthesia, but forgot to return to monitor the animal's recovery -as a result, it was left all night without food and water. In another case, a project licence holder used 30% more non-human primates than were authorised. In a further case, a project licence permitted a total of 5,000 geneticallyaltered (GA) mice to be used during the five-year duration of the project, but 11,000 mice had been used within two years. In another project, approval was given for an estimated 127,600 mice to be used, but this number was exceeded by 179,546 mice. In other similar cases, 225,940 mice were used, rather than the 200,000 authorised, and 2,410 mice were used, rather than the permitted 2,200.
The 'punishment' given to the non-compliant licensees was usually a written reprimand, but, given the scale of some of the incidents, one is entitled to ask why the Home Office Inspectors were not aware of what was going on. Also, given the scale of animal use, some of the cases involved what must have been large institutions, which, like some of the personal and project licensees, were fortunate not to have their licences withdrawn.
Despite what we have described, selecting Policy; Animal Research and Testing while browsing in the Home Office website (https://www.gov.uk/government/policies/animal-research-and-testing), results in the following statement: "Our regulations ensure that animals are used in scientific procedures only when there's no validated alternative and when the potential benefits outweigh the harms. We are committed to: using non-animal alternatives wherever possible; reducing the number of animals used to the minimum needed; refining procedures as much as possible to minimise suffering."
The latest ASRU Report 1 and the 2016 Annual Statistics 2 strongly suggest to us that this laudable objective of implementing all of the Three Rs is far from being a level playing field. For example, the search term, replacement, resulted in just nine hits, of which all were contextual with the two other Rs, which themselves were both mentioned with a much higher frequency, and invariably in relation to a particular new ongoing governmentfunded investigation. While this, in itself, is to be applauded, it masks the fact that no research projects specifically aimed at developing and encouraging the use of replacement methods, were available for inclusion in the report.
Russell and Burch 6 noted that replacement is nearly always the hardest of the Three Rs to achieve, but this should not deter efforts to find non-animal alternatives, as this is the only satisfactory ultimate objective for both human and animal welfare and for scientific reasons. However, matters are not helped by the wording of the Home Office pro forma required to be completed by all designated establishments applying for project licences, to provide non-technical summaries, as required by the ASPA. This wording says: "State why you need to use animals and why you cannot use non-animal alternatives". Looking at these summaries for 2016 and earlier on the Home Office website, it is clear that the standard explanation that there are 'no valid alternatives' occurs repeatedly for the same procedures. How is such a situation going to change when there is no pressure on those using animals to find and develop replacement methods themselves, unless someone else, by chance, provides a relevant and reliable alternative? In other words, project licence applicants should themselves be encouraged to take action in this direction, by having to explain, in detail, what steps they have taken to pro-actively find non-animal strategies. After all, as end-users of any such methods, they should be well-placed to overcome the barriers to replacement.
A further major concern is the strong impression from the Home Office report that the relentless rise in the diversity and numbers of GA animals will continue, almost completely unchallenged, despite legitimate scientific and welfare objections. This is despite the fact that, for many severe human disease conditions, animal models continue to be developed and used, in the absence of sufficient understanding either of the diseases themselves or of the relevance of the models, with the result that the discovery of effective therapies, let alone cures, remains as intractable as ever.
We recognise that much is going on to ensure that the ASPA is as effective as possible, but there is still a great deal to be done, and we cannot help feeling that the Minister of State is being let down by some of those from whom she is entitled to have support. Not least among them is the animal experimentation industry (yes, that's what it is), which claims to be committed to the Three Rs, but strives to damp down any criticism, and claims that animal procedures are more valuable than they really are, without being required to openly provide the evidence to justify that claim.
